Share Price and Basic Stock Data
Last Updated: February 12, 2026, 8:53 pm
| PEG Ratio | -30.97 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ipca Laboratories Ltd, a prominent player in the pharmaceuticals industry, reported a current price of ₹1,433 and a market capitalization of ₹36,343 Cr. The company has demonstrated robust revenue growth, with sales increasing from ₹5,797 Cr in March 2022 to ₹6,204 Cr in March 2023, and projected to rise to ₹8,897 Cr by March 2025. This upward trajectory highlights Ipca’s effective market strategies and product offerings. The quarterly sales figures show notable fluctuations, with a significant jump to ₹2,034 Cr in September 2023, up from ₹1,512 Cr in March 2023. This reflects strong demand and effective operational execution. The company’s operating profit margin (OPM) has varied, standing at 21% currently, which is competitive within the sector, as typical margins often range between 15% and 20%. The consistent increase in revenues underscores Ipca’s potential for expansion, driven by both domestic and international markets.
Profitability and Efficiency Metrics
Ipca Laboratories recorded a net profit of ₹854 Cr, with a P/E ratio of 36.7, indicating a premium valuation relative to its earnings. The company’s return on equity (ROE) stood at 12.8%, while return on capital employed (ROCE) was reported at 14.7%. These figures are indicative of efficient capital management and profitability relative to shareholder investments. The operating profit surged to ₹1,731 Cr for March 2025, with an OPM of 19%, demonstrating effective cost management alongside revenue growth. However, the cash conversion cycle (CCC) has lengthened to 302 days, suggesting challenges in managing working capital efficiently. Additionally, the interest coverage ratio (ICR) of 21.42x is notably high, indicating that the company can comfortably meet its interest obligations. Overall, while the profitability metrics are strong, the increasing CCC may pose risks to liquidity and operational efficiency.
Balance Sheet Strength and Financial Ratios
Ipca’s balance sheet exhibits a solid foundation, with total assets amounting to ₹12,263 Cr and reserves of ₹7,402 Cr as of September 2025. The company has maintained borrowings at ₹1,279 Cr, reflecting a conservative leverage strategy with a total debt-to-equity ratio of 0.18, well below typical industry benchmarks. The current ratio of 2.63 suggests strong liquidity, enabling the company to cover its short-term obligations comfortably. Furthermore, the interest coverage ratio of 21.42x indicates a strong ability to service debt, which is favorable compared to industry norms. However, the declining book value per share from ₹371.79 in March 2021 to ₹273.88 in March 2025 raises concerns about long-term asset sustainability. The efficiency ratios, particularly the inventory turnover ratio of 3.55, signal effective inventory management, yet the increasing days payable at 111 days could indicate potential liquidity strains in the future.
Shareholding Pattern and Investor Confidence
The shareholding structure of Ipca Laboratories reflects a balanced distribution, with promoters holding 44.72% of the shares, while foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold 10.42% and 36.45%, respectively. This distribution indicates a strong institutional backing, which typically enhances investor confidence. However, the promoter holding has slightly decreased from 46.29% in December 2022 to the current level, which may raise concerns about management’s commitment to the company. The number of shareholders has declined to 82,870, which could suggest a consolidation phase or reduced retail investor interest. The dividend payout ratio of 13.75% for March 2025 indicates a commitment to returning value to shareholders, although it is lower than the previous year, reflecting a cautious approach towards capital allocation amidst growth investments. Overall, while institutional interest remains robust, the decline in promoter shareholding may raise flags for some investors.
Outlook, Risks, and Final Insight
The outlook for Ipca Laboratories appears positive, driven by strong revenue growth and solid profitability metrics. However, several risks need to be considered. The increasing cash conversion cycle could impact liquidity if not managed effectively, while the declining book value per share necessitates scrutiny regarding asset management and long-term sustainability. Additionally, fluctuations in global drug pricing and regulatory challenges could impact revenue stability. If the company can successfully navigate these challenges while maintaining its growth trajectory, it may continue to enhance shareholder value. Conversely, failure to address these risks could hinder performance, affecting investor sentiment. The balance of strong institutional support versus potential concerns about management commitment and efficiency will be crucial in shaping the company’s future performance. Investors should monitor operational efficiency closely, particularly in terms of working capital management, to ensure sustained growth and profitability.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 133 Cr. | 106 | 158/84.3 | 29.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.15/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,451 Cr. | 319 | 479/192 | 72.2 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 30.6 Cr. | 41.3 | 79.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 82.8 Cr. | 56.5 | 56.7/17.0 | 197 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,994.39 Cr | 1,109.18 | 54.25 | 201.93 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,601 | 1,546 | 1,512 | 1,585 | 2,034 | 2,053 | 2,033 | 2,093 | 2,355 | 2,245 | 2,247 | 2,309 | 2,556 |
| Expenses | 1,341 | 1,330 | 1,331 | 1,278 | 1,673 | 1,722 | 1,711 | 1,700 | 1,913 | 1,782 | 1,818 | 1,892 | 2,012 |
| Operating Profit | 260 | 216 | 181 | 308 | 361 | 331 | 322 | 393 | 441 | 463 | 429 | 416 | 545 |
| OPM % | 16% | 14% | 12% | 19% | 18% | 16% | 16% | 19% | 19% | 21% | 19% | 18% | 21% |
| Other Income | 36 | 31 | 36 | 45 | -1 | 91 | -118 | 21 | 26 | 20 | -179 | 33 | -30 |
| Interest | 9 | 11 | 18 | 31 | 44 | 33 | 29 | 24 | 23 | 17 | 22 | 19 | 20 |
| Depreciation | 64 | 67 | 70 | 69 | 90 | 100 | 98 | 99 | 100 | 98 | 100 | 100 | 103 |
| Profit before tax | 223 | 169 | 129 | 252 | 225 | 289 | 77 | 290 | 345 | 368 | 128 | 331 | 392 |
| Tax % | 35% | 32% | 37% | 34% | 39% | 23% | 96% | 31% | 29% | 25% | 49% | 29% | 28% |
| Net Profit | 146 | 110 | 78 | 164 | 136 | 221 | 1 | 199 | 246 | 276 | 64 | 233 | 281 |
| EPS in Rs | 5.67 | 4.25 | 3.02 | 6.42 | 5.72 | 7.09 | 2.35 | 7.58 | 9.05 | 9.78 | 2.67 | 9.19 | 11.14 |
Last Updated: January 1, 2026, 6:16 am
Below is a detailed analysis of the quarterly data for Ipca Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 2,556.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,309.00 Cr. (Jun 2025) to 2,556.00 Cr., marking an increase of 247.00 Cr..
- For Expenses, as of Sep 2025, the value is 2,012.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,892.00 Cr. (Jun 2025) to 2,012.00 Cr., marking an increase of 120.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 545.00 Cr.. The value appears strong and on an upward trend. It has increased from 416.00 Cr. (Jun 2025) to 545.00 Cr., marking an increase of 129.00 Cr..
- For OPM %, as of Sep 2025, the value is 21.00%. The value appears strong and on an upward trend. It has increased from 18.00% (Jun 2025) to 21.00%, marking an increase of 3.00%.
- For Other Income, as of Sep 2025, the value is -30.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Jun 2025) to -30.00 Cr., marking a decrease of 63.00 Cr..
- For Interest, as of Sep 2025, the value is 20.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 19.00 Cr. (Jun 2025) to 20.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 103.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 100.00 Cr. (Jun 2025) to 103.00 Cr., marking an increase of 3.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 392.00 Cr.. The value appears strong and on an upward trend. It has increased from 331.00 Cr. (Jun 2025) to 392.00 Cr., marking an increase of 61.00 Cr..
- For Tax %, as of Sep 2025, the value is 28.00%. The value appears to be improving (decreasing) as expected. It has decreased from 29.00% (Jun 2025) to 28.00%, marking a decrease of 1.00%.
- For Net Profit, as of Sep 2025, the value is 281.00 Cr.. The value appears strong and on an upward trend. It has increased from 233.00 Cr. (Jun 2025) to 281.00 Cr., marking an increase of 48.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 11.14. The value appears strong and on an upward trend. It has increased from 9.19 (Jun 2025) to 11.14, marking an increase of 1.95.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:10 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,282 | 3,144 | 2,867 | 3,156 | 3,258 | 3,746 | 4,619 | 5,395 | 5,797 | 6,204 | 7,662 | 8,897 | 9,357 |
| Expenses | 2,539 | 2,604 | 2,573 | 2,705 | 2,803 | 3,051 | 3,715 | 3,843 | 4,472 | 5,272 | 6,338 | 7,166 | 7,504 |
| Operating Profit | 743 | 541 | 294 | 451 | 455 | 695 | 904 | 1,552 | 1,325 | 932 | 1,324 | 1,731 | 1,853 |
| OPM % | 23% | 17% | 10% | 14% | 14% | 19% | 20% | 29% | 23% | 15% | 17% | 19% | 20% |
| Other Income | 21 | 32 | 21 | 11 | 41 | 56 | 65 | 59 | 54 | 123 | 17 | -114 | -157 |
| Interest | 30 | 32 | 35 | 27 | 28 | 22 | 20 | 12 | 11 | 48 | 141 | 88 | 76 |
| Depreciation | 103 | 180 | 163 | 173 | 178 | 182 | 210 | 209 | 232 | 262 | 357 | 398 | 402 |
| Profit before tax | 631 | 361 | 117 | 262 | 291 | 546 | 739 | 1,389 | 1,136 | 745 | 843 | 1,131 | 1,218 |
| Tax % | 24% | 28% | 18% | 26% | 18% | 19% | 18% | 17% | 20% | 34% | 37% | 30% | |
| Net Profit | 479 | 254 | 93 | 195 | 239 | 442 | 604 | 1,141 | 890 | 479 | 523 | 785 | 854 |
| EPS in Rs | 18.96 | 10.07 | 3.69 | 7.71 | 9.49 | 17.60 | 23.99 | 44.94 | 34.85 | 18.58 | 21.57 | 29.08 | 32.78 |
| Dividend Payout % | 13% | 5% | 0% | 6% | 5% | 9% | 10% | 9% | 11% | 22% | 19% | 14% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -46.97% | -63.39% | 109.68% | 22.56% | 84.94% | 36.65% | 88.91% | -22.00% | -46.18% | 9.19% | 50.10% |
| Change in YoY Net Profit Growth (%) | 0.00% | -16.41% | 173.06% | -87.11% | 62.37% | -48.29% | 52.26% | -110.91% | -24.18% | 55.37% | 40.91% |
Ipca Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 14% |
| 3 Years: | 15% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 7% |
| 3 Years: | -1% |
| TTM: | 44% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 6% |
| 3 Years: | 15% |
| 1 Year: | -7% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 14% |
| 3 Years: | 10% |
| Last Year: | 13% |
Last Updated: September 5, 2025, 7:50 am
Balance Sheet
Last Updated: December 4, 2025, 1:27 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
| Reserves | 1,934 | 2,183 | 2,234 | 2,430 | 2,663 | 3,097 | 3,602 | 4,676 | 5,439 | 5,817 | 6,307 | 6,923 | 7,402 |
| Borrowings | 603 | 935 | 867 | 716 | 628 | 465 | 501 | 265 | 807 | 1,481 | 1,438 | 1,363 | 1,279 |
| Other Liabilities | 648 | 669 | 765 | 788 | 799 | 961 | 1,130 | 1,099 | 1,349 | 1,300 | 3,326 | 3,432 | 3,557 |
| Total Liabilities | 3,211 | 3,812 | 3,892 | 3,960 | 4,116 | 4,549 | 5,258 | 6,066 | 7,622 | 8,623 | 11,097 | 11,744 | 12,263 |
| Fixed Assets | 1,354 | 1,800 | 2,014 | 1,983 | 1,953 | 1,940 | 2,059 | 2,072 | 2,402 | 2,751 | 4,554 | 4,267 | 4,371 |
| CWIP | 165 | 267 | 129 | 95 | 73 | 66 | 133 | 235 | 306 | 140 | 343 | 622 | 777 |
| Investments | 9 | 16 | 26 | 136 | 87 | 120 | 310 | 505 | 989 | 626 | 862 | 980 | 1,203 |
| Other Assets | 1,683 | 1,729 | 1,723 | 1,746 | 2,003 | 2,422 | 2,756 | 3,254 | 3,924 | 5,105 | 5,339 | 5,875 | 5,912 |
| Total Assets | 3,211 | 3,812 | 3,892 | 3,960 | 4,116 | 4,549 | 5,258 | 6,066 | 7,622 | 8,623 | 11,097 | 11,744 | 12,263 |
Below is a detailed analysis of the balance sheet data for Ipca Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 25.00 Cr..
- For Reserves, as of Sep 2025, the value is 7,402.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,923.00 Cr. (Mar 2025) to 7,402.00 Cr., marking an increase of 479.00 Cr..
- For Borrowings, as of Sep 2025, the value is 1,279.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 1,363.00 Cr. (Mar 2025) to 1,279.00 Cr., marking a decrease of 84.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 3,557.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,432.00 Cr. (Mar 2025) to 3,557.00 Cr., marking an increase of 125.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 12,263.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11,744.00 Cr. (Mar 2025) to 12,263.00 Cr., marking an increase of 519.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 4,371.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,267.00 Cr. (Mar 2025) to 4,371.00 Cr., marking an increase of 104.00 Cr..
- For CWIP, as of Sep 2025, the value is 777.00 Cr.. The value appears strong and on an upward trend. It has increased from 622.00 Cr. (Mar 2025) to 777.00 Cr., marking an increase of 155.00 Cr..
- For Investments, as of Sep 2025, the value is 1,203.00 Cr.. The value appears strong and on an upward trend. It has increased from 980.00 Cr. (Mar 2025) to 1,203.00 Cr., marking an increase of 223.00 Cr..
- For Other Assets, as of Sep 2025, the value is 5,912.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,875.00 Cr. (Mar 2025) to 5,912.00 Cr., marking an increase of 37.00 Cr..
- For Total Assets, as of Sep 2025, the value is 12,263.00 Cr.. The value appears strong and on an upward trend. It has increased from 11,744.00 Cr. (Mar 2025) to 12,263.00 Cr., marking an increase of 519.00 Cr..
Notably, the Reserves (7,402.00 Cr.) exceed the Borrowings (1,279.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 140.00 | -394.00 | -573.00 | -265.00 | -173.00 | 230.00 | 403.00 | -264.00 | -806.00 | 931.00 | 0.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 50 | 41 | 57 | 58 | 67 | 66 | 71 | 55 | 57 | 58 | 80 | 77 |
| Inventory Days | 272 | 293 | 289 | 290 | 286 | 316 | 294 | 337 | 337 | 276 | 350 | 336 |
| Days Payable | 110 | 97 | 145 | 130 | 137 | 154 | 135 | 140 | 101 | 83 | 110 | 111 |
| Cash Conversion Cycle | 213 | 237 | 200 | 218 | 216 | 228 | 229 | 251 | 293 | 251 | 321 | 302 |
| Working Capital Days | 82 | 68 | 61 | 74 | 80 | 88 | 88 | 103 | 102 | 71 | 111 | 101 |
| ROCE % | 28% | 14% | 5% | 9% | 10% | 16% | 19% | 31% | 20% | 11% | 13% | 15% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Mid Cap Fund | 17,920,369 | 2.74 | 2542.72 | 17,846,931 | 2026-01-26 03:17:01 | 0.41% |
| Kotak Midcap Fund | 12,005,038 | 2.81 | 1703.39 | N/A | N/A | N/A |
| DSP Mid Cap Fund | 4,637,728 | 3.36 | 658.05 | 5,164,736 | 2025-12-08 06:09:34 | -10.2% |
| Nippon India Growth Mid Cap Fund | 3,100,000 | 1.04 | 439.86 | N/A | N/A | N/A |
| Kotak Large & Midcap Fund | 2,510,000 | 1.19 | 356.14 | N/A | N/A | N/A |
| HDFC Balanced Advantage Fund | 2,497,123 | 0.33 | 354.32 | N/A | N/A | N/A |
| DSP Small Cap Fund | 2,320,000 | 1.94 | 329.18 | 2,572,727 | 2025-12-08 06:09:34 | -9.82% |
| DSP Large & Mid Cap Fund | 1,950,196 | 1.57 | 276.71 | N/A | N/A | N/A |
| DSP ELSS Tax Saver Fund | 1,857,399 | 1.5 | 263.55 | 1,681,026 | 2025-12-08 06:09:34 | 10.49% |
| Axis Midcap Fund | 1,810,234 | 0.81 | 256.85 | 1,781,240 | 2026-01-26 05:00:11 | 1.63% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 |
| Basic EPS (Rs.) | 35.14 | 25.82 | 18.58 | 34.85 | 45.01 |
| Diluted EPS (Rs.) | 29.08 | 21.57 | 18.58 | 34.85 | 45.01 |
| Cash EPS (Rs.) | 46.72 | 34.94 | 29.70 | 45.07 | 107.06 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 273.88 | 304.57 | 233.16 | 219.51 | 371.79 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 273.88 | 304.57 | 233.16 | 219.51 | 371.79 |
| Revenue From Operations / Share (Rs.) | 352.37 | 303.71 | 246.13 | 229.79 | 427.28 |
| PBDIT / Share (Rs.) | 71.70 | 56.99 | 41.48 | 54.23 | 126.70 |
| PBIT / Share (Rs.) | 56.02 | 42.91 | 31.17 | 45.07 | 110.21 |
| PBT / Share (Rs.) | 44.59 | 33.22 | 29.38 | 44.77 | 109.50 |
| Net Profit / Share (Rs.) | 31.04 | 20.86 | 19.39 | 35.91 | 90.57 |
| NP After MI And SOA / Share (Rs.) | 29.08 | 21.57 | 18.58 | 34.85 | 89.87 |
| PBDIT Margin (%) | 20.34 | 18.76 | 16.85 | 23.59 | 29.65 |
| PBIT Margin (%) | 15.89 | 14.12 | 12.66 | 19.61 | 25.79 |
| PBT Margin (%) | 12.65 | 10.93 | 11.93 | 19.48 | 25.62 |
| Net Profit Margin (%) | 8.80 | 6.86 | 7.87 | 15.62 | 21.19 |
| NP After MI And SOA Margin (%) | 8.25 | 7.10 | 7.54 | 15.16 | 21.03 |
| Return on Networth / Equity (%) | 10.61 | 8.64 | 8.06 | 16.09 | 24.24 |
| Return on Capital Employeed (%) | 15.15 | 12.44 | 11.59 | 18.52 | 28.48 |
| Return On Assets (%) | 6.27 | 4.93 | 5.46 | 11.57 | 18.78 |
| Long Term Debt / Equity (X) | 0.07 | 0.09 | 0.11 | 0.07 | 0.00 |
| Total Debt / Equity (X) | 0.18 | 0.21 | 0.24 | 0.14 | 0.05 |
| Asset Turnover Ratio (%) | 0.78 | 0.78 | 0.76 | 0.79 | 0.91 |
| Current Ratio (X) | 2.63 | 2.35 | 2.87 | 3.04 | 2.96 |
| Quick Ratio (X) | 1.55 | 1.30 | 1.91 | 1.77 | 1.59 |
| Inventory Turnover Ratio (X) | 3.55 | 1.05 | 0.94 | 0.95 | 1.10 |
| Dividend Payout Ratio (NP) (%) | 13.75 | 9.27 | 21.53 | 11.47 | 8.90 |
| Dividend Payout Ratio (CP) (%) | 8.93 | 5.60 | 13.84 | 9.08 | 7.52 |
| Earning Retention Ratio (%) | 86.25 | 90.73 | 78.47 | 88.53 | 91.10 |
| Cash Earning Retention Ratio (%) | 91.07 | 94.40 | 86.16 | 90.92 | 92.48 |
| Interest Coverage Ratio (X) | 21.42 | 10.46 | 23.11 | 178.91 | 177.79 |
| Interest Coverage Ratio (Post Tax) (X) | 12.69 | 5.61 | 11.80 | 119.46 | 128.08 |
| Enterprise Value (Cr.) | 40485.27 | 33899.87 | 20234.90 | 27148.88 | 24038.82 |
| EV / Net Operating Revenue (X) | 4.53 | 4.40 | 3.24 | 4.66 | 4.44 |
| EV / EBITDA (X) | 22.26 | 23.45 | 19.23 | 19.73 | 14.96 |
| MarketCap / Net Operating Revenue (X) | 4.26 | 4.08 | 3.29 | 4.62 | 4.45 |
| Retention Ratios (%) | 86.24 | 90.72 | 78.46 | 88.52 | 91.09 |
| Price / BV (X) | 5.48 | 4.96 | 3.52 | 4.90 | 5.13 |
| Price / Net Operating Revenue (X) | 4.26 | 4.08 | 3.29 | 4.62 | 4.45 |
| EarningsYield | 0.01 | 0.01 | 0.02 | 0.03 | 0.04 |
After reviewing the key financial ratios for Ipca Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 35.14. This value is within the healthy range. It has increased from 25.82 (Mar 24) to 35.14, marking an increase of 9.32.
- For Diluted EPS (Rs.), as of Mar 25, the value is 29.08. This value is within the healthy range. It has increased from 21.57 (Mar 24) to 29.08, marking an increase of 7.51.
- For Cash EPS (Rs.), as of Mar 25, the value is 46.72. This value is within the healthy range. It has increased from 34.94 (Mar 24) to 46.72, marking an increase of 11.78.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 273.88. It has decreased from 304.57 (Mar 24) to 273.88, marking a decrease of 30.69.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 273.88. It has decreased from 304.57 (Mar 24) to 273.88, marking a decrease of 30.69.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 352.37. It has increased from 303.71 (Mar 24) to 352.37, marking an increase of 48.66.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 71.70. This value is within the healthy range. It has increased from 56.99 (Mar 24) to 71.70, marking an increase of 14.71.
- For PBIT / Share (Rs.), as of Mar 25, the value is 56.02. This value is within the healthy range. It has increased from 42.91 (Mar 24) to 56.02, marking an increase of 13.11.
- For PBT / Share (Rs.), as of Mar 25, the value is 44.59. This value is within the healthy range. It has increased from 33.22 (Mar 24) to 44.59, marking an increase of 11.37.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 31.04. This value is within the healthy range. It has increased from 20.86 (Mar 24) to 31.04, marking an increase of 10.18.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 29.08. This value is within the healthy range. It has increased from 21.57 (Mar 24) to 29.08, marking an increase of 7.51.
- For PBDIT Margin (%), as of Mar 25, the value is 20.34. This value is within the healthy range. It has increased from 18.76 (Mar 24) to 20.34, marking an increase of 1.58.
- For PBIT Margin (%), as of Mar 25, the value is 15.89. This value is within the healthy range. It has increased from 14.12 (Mar 24) to 15.89, marking an increase of 1.77.
- For PBT Margin (%), as of Mar 25, the value is 12.65. This value is within the healthy range. It has increased from 10.93 (Mar 24) to 12.65, marking an increase of 1.72.
- For Net Profit Margin (%), as of Mar 25, the value is 8.80. This value is within the healthy range. It has increased from 6.86 (Mar 24) to 8.80, marking an increase of 1.94.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.25. This value is within the healthy range. It has increased from 7.10 (Mar 24) to 8.25, marking an increase of 1.15.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.61. This value is below the healthy minimum of 15. It has increased from 8.64 (Mar 24) to 10.61, marking an increase of 1.97.
- For Return on Capital Employeed (%), as of Mar 25, the value is 15.15. This value is within the healthy range. It has increased from 12.44 (Mar 24) to 15.15, marking an increase of 2.71.
- For Return On Assets (%), as of Mar 25, the value is 6.27. This value is within the healthy range. It has increased from 4.93 (Mar 24) to 6.27, marking an increase of 1.34.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 0.2. It has decreased from 0.09 (Mar 24) to 0.07, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.18. This value is within the healthy range. It has decreased from 0.21 (Mar 24) to 0.18, marking a decrease of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.78. There is no change compared to the previous period (Mar 24) which recorded 0.78.
- For Current Ratio (X), as of Mar 25, the value is 2.63. This value is within the healthy range. It has increased from 2.35 (Mar 24) to 2.63, marking an increase of 0.28.
- For Quick Ratio (X), as of Mar 25, the value is 1.55. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.55, marking an increase of 0.25.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.55. This value is below the healthy minimum of 4. It has increased from 1.05 (Mar 24) to 3.55, marking an increase of 2.50.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 13.75. This value is below the healthy minimum of 20. It has increased from 9.27 (Mar 24) to 13.75, marking an increase of 4.48.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.93. This value is below the healthy minimum of 20. It has increased from 5.60 (Mar 24) to 8.93, marking an increase of 3.33.
- For Earning Retention Ratio (%), as of Mar 25, the value is 86.25. This value exceeds the healthy maximum of 70. It has decreased from 90.73 (Mar 24) to 86.25, marking a decrease of 4.48.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.07. This value exceeds the healthy maximum of 70. It has decreased from 94.40 (Mar 24) to 91.07, marking a decrease of 3.33.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 21.42. This value is within the healthy range. It has increased from 10.46 (Mar 24) to 21.42, marking an increase of 10.96.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 12.69. This value is within the healthy range. It has increased from 5.61 (Mar 24) to 12.69, marking an increase of 7.08.
- For Enterprise Value (Cr.), as of Mar 25, the value is 40,485.27. It has increased from 33,899.87 (Mar 24) to 40,485.27, marking an increase of 6,585.40.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.53. This value exceeds the healthy maximum of 3. It has increased from 4.40 (Mar 24) to 4.53, marking an increase of 0.13.
- For EV / EBITDA (X), as of Mar 25, the value is 22.26. This value exceeds the healthy maximum of 15. It has decreased from 23.45 (Mar 24) to 22.26, marking a decrease of 1.19.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.26. This value exceeds the healthy maximum of 3. It has increased from 4.08 (Mar 24) to 4.26, marking an increase of 0.18.
- For Retention Ratios (%), as of Mar 25, the value is 86.24. This value exceeds the healthy maximum of 70. It has decreased from 90.72 (Mar 24) to 86.24, marking a decrease of 4.48.
- For Price / BV (X), as of Mar 25, the value is 5.48. This value exceeds the healthy maximum of 3. It has increased from 4.96 (Mar 24) to 5.48, marking an increase of 0.52.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.26. This value exceeds the healthy maximum of 3. It has increased from 4.08 (Mar 24) to 4.26, marking an increase of 0.18.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ipca Laboratories Ltd:
- Net Profit Margin: 8.8%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 15.15% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.61% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 12.69
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.55
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 37.7 (Industry average Stock P/E: 54.25)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.18
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.8%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 48, Kandivli Industrial Estate, Kandivli (West), Mumbai Maharashtra 400067 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Premchand Godha | Executive Chairman |
| Mr. Ajit Kumar Jain | Managing Director & CFO |
| Mr. Pranay Godha | Managing Director & CEO |
| Mr. Prashant Godha | Executive Director |
| Dr.(Ms.) Swati Patankar | Independent Director |
| Dr. Narendra Mairpady | Independent Director |
| Mr. Vivek Shiralkar | Independent Director |
| Mr. Kamal Kishore Seth | Independent Director |
FAQ
What is the intrinsic value of Ipca Laboratories Ltd?
Ipca Laboratories Ltd's intrinsic value (as of 12 February 2026) is ₹1120.36 which is 23.94% lower the current market price of ₹1,473.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹37,352 Cr. market cap, FY2025-2026 high/low of ₹1,595/1,168, reserves of ₹7,402 Cr, and liabilities of ₹12,263 Cr.
What is the Market Cap of Ipca Laboratories Ltd?
The Market Cap of Ipca Laboratories Ltd is 37,352 Cr..
What is the current Stock Price of Ipca Laboratories Ltd as on 12 February 2026?
The current stock price of Ipca Laboratories Ltd as on 12 February 2026 is ₹1,473.
What is the High / Low of Ipca Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ipca Laboratories Ltd stocks is ₹1,595/1,168.
What is the Stock P/E of Ipca Laboratories Ltd?
The Stock P/E of Ipca Laboratories Ltd is 37.7.
What is the Book Value of Ipca Laboratories Ltd?
The Book Value of Ipca Laboratories Ltd is 293.
What is the Dividend Yield of Ipca Laboratories Ltd?
The Dividend Yield of Ipca Laboratories Ltd is 0.27 %.
What is the ROCE of Ipca Laboratories Ltd?
The ROCE of Ipca Laboratories Ltd is 14.7 %.
What is the ROE of Ipca Laboratories Ltd?
The ROE of Ipca Laboratories Ltd is 12.8 %.
What is the Face Value of Ipca Laboratories Ltd?
The Face Value of Ipca Laboratories Ltd is 1.00.